&Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

&Partners’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$4.79K	–	2121
2025 Q2	$4.79K	Buy	+20,000	New	+$5.34K	﹤0.01%	1991

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

&Partners's ADAP Position: Q3 2025 in Review

&Partners sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 20,000 shares — an estimated $4.79K sold.

&Partners first reported a position in ADAP in Q2 2025 and held it in 1 quarter. The position peaked at $4.79K in Q2 2025. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

&Partners reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
&Partners sold 20,000 Adaptimmune Therapeutics shares in Q3 2025, an estimated $4.79K.
&Partners first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 1 quarter.
&Partners's Adaptimmune Therapeutics position peaked at $4.79K in Q2 2025.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on &Partners's 13F filing for Q3 2025, filed 14 Nov 2025.